Eurofins Scientific (ERFS.F) Stock Overview
Provides various analytical testing and laboratory services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
ERFS.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Eurofins Scientific SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €75.03 |
| 52 Week High | €86.20 |
| 52 Week Low | €54.01 |
| Beta | 0.91 |
| 1 Month Change | 4.94% |
| 3 Month Change | -11.88% |
| 1 Year Change | 29.81% |
| 3 Year Change | 11.42% |
| 5 Year Change | -33.31% |
| Change since IPO | 381.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERFS.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.9% | 3.5% | 4.2% |
| 1Y | 29.8% | 9.2% | 29.0% |
Return vs Industry: ERFS.F exceeded the US Life Sciences industry which returned 7.5% over the past year.
Return vs Market: ERFS.F exceeded the US Market which returned 27.4% over the past year.
Price Volatility
| ERFS.F volatility | |
|---|---|
| ERFS.F Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ERFS.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ERFS.F's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 65,694 | Gilles Martin | www.eurofins.com |
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services.
Eurofins Scientific SE Fundamentals Summary
| ERFS.F fundamental statistics | |
|---|---|
| Market cap | US$13.43b |
| Earnings (TTM) | US$489.36m |
| Revenue (TTM) | US$8.58b |
Is ERFS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERFS.F income statement (TTM) | |
|---|---|
| Revenue | €7.30b |
| Cost of Revenue | €5.66b |
| Gross Profit | €1.64b |
| Other Expenses | €1.22b |
| Earnings | €416.10m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.37 |
| Gross Margin | 22.49% |
| Net Profit Margin | 5.70% |
| Debt/Equity Ratio | 87.3% |
How did ERFS.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 10:02 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eurofins Scientific SE is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hubert D'Aillieres | Banco BPI, S.A. |
| James Rowland Clark | Barclays |
| James Rosenthal | Barclays |